Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 11-27, February 2000

Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem

Department of Endocrinology and Metabolic Diseases C4-86, Leiden University Medical Center, Leiden, ZA, 2333, The Netherlands

Abstract 

Breast cancer metastasizes frequently to the skeleton and causes considerable morbidity and deterioration of the quality of life. The clinical consequences of skeletal metastases are bone pain, pathological fractures, hypercalcaemia and nerve compression syndromes. From the moment breast cancer cells are located in the bone microenvironment, they may release factors which stimulate bone resorption and angiogenesis leading to growth of skeletal metastases and a subsequent selective increase in the attraction of new cancer cells to bone.

In this review, emerging new concepts of breast cancer–bone interactions, in particular the involvement of angiogenesis, proteolysis and the role of cancer-induced bone resorption in skeletal metastasis are discussed. Better understanding of the processes involved in the metastasis of cancer cells to bone, local tumour growth and subsequent destruction of skeletal architecture can lead to optimal methods for the prevention and treatment of metastatic bone disease.

Keywords: Breast neoplasms, neoplasm metastasis, bone metastasis, metastatic bone disease, pathologic neovascularization, angiogenesis, peptide peptidohydrolases, osteoclasts, cell surface receptors, extracellular matrix.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Address all correspondence to: Dr. Gabri van der Pluijm, Leiden University Medical Center (LUMC), Department of Endocrinology & Metabolic Diseases C4-R, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.

PII: S0305-7372(99)90143-3

doi:10.1053/ctrv.1999.0143

Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 11-27, February 2000